McKesson Corporation and HCA Healthcare plan to form a joint venture combining McKesson’s US Oncology Research and HCA Healthcare’s Sarah Cannon Research Institute.
USOR is the research arm of McKesson’s The US Oncology Network specializing in clinical trials. SCRI, which is the research arm of Sarah Cannon, HCA Healthcare’s Cancer Institute, offers end-to-end clinical trial site support services with expertise in early-phase oncology research and drug development as well as a specialized contract research organization.
The transaction is expected to close this year. Following the close of the transaction, McKesson will own 51% of the joint venture and have operating control. Read more.
